Acquisition Impact Tempus AI acquired Deep 6 AI in February 2025, indicating a potential cross-sell opportunity to integrate Deep 6’s patient matching capabilities within Tempus’ broader data and network, expanding reach to over 750 provider sites and tens of millions of patients.

Clinical Trial Network Deep 6 AI already works with prominent health systems, pharma companies, and CROs, suggesting strong footholds for enterprise-level deals and multi-site licenses; leverage existing relationships to upsell expanded trial enrollment capabilities.

AI-Driven Advantage The core value proposition centers on rapid, high-accuracy matching of eligible patients using AI and NLP; sales can focus on faster trial startup, improved enrollment timelines, and reduced screening costs for sponsors and sites.

Growth Readiness With funding of around $50M and revenue in the mid single to mid double digits, there is room to scale partnerships and expand product deployments; align proposals with potential ROI through efficiency gains and faster trial cycles.

Strategic Partnerships Past collaborations with Graticule and Genomenon, plus engagement in CNS Summit events, indicate a pattern of forming data-driven alliances; approach similar data partners and life sciences networks to broaden the platform’s data sources and use cases.